What’s on at the BCLA conference?

OT  rounds up news from manufacturers as the BCLA conference begins

contact lens on finger

The BCLA Clinical Conference & Exhibition begins today (9–11 June) at Manchester Central.

OT rounds up plans for the show shared by contact lens manufacturers and researchers in the field.

CooperVision: improving lives

Platinum-level sponsor for the event, CooperVision, will focus on “improving lives, one person at a time.”

The company will highlight its contact lens options, while its stand will highlight a four point approach to plastic circularity: design, source, recover, and offset.

Information on the company’s offsetting programme, currently live in 27 countries, will also be available.

CooperVision will present 20 research papers and posters, covering topics from myopia management, to toric contact lenses, and opportunities for contact lens fitting.

The manufacturer will present a range of research into myopia management, including Dual Focus Contact Lenses Deliver a Myopia Control Signal to the Retinas of Highly Myopic Eyes (Nguyen M., et al.), and Case Series on Myopia Progression in Children Beyond a Period of No Treatment Following 3 or 6 Years of MiSight 1 day Treatment (Logan N., Jones S.).

Young adult acceptance of dual focus soft contact lenses for myopia management is also explored, along with supporting successful fitting of orthokeratology, toric lenses and astigmatism.

CooperVision’s research collaborators at the BCLA Conference include the School of Optometry at Aston University, the Centre for Ocular Research and Education (CORE), Eurolens Research, Indiana University, Ocular Technology Group – International, and the University of New South Wales.

Johnson & Johnson Vision on technological features

Johnson & Johnson Vision will host two feature presentations, along with a variety of free paper and poster sessions.

Sustainability remains a focus, as the stand will be built with materials re-used from previous events and will be 100% paperless.

The company, part of Johnson & Johnson MedTech, will share new data on the technological features of Acuvue Oasys MAX 1-Day and Acuvue Oasys MAX 1-Day Multifocal contact lenses.

This will include a focus on a new technology introduced to the lens, which supports the filtering of high-energy visible light.

Johnson & Johnson Vision will host interactive education and demonstrations from its booth, including an Acuvue Virtual Reality vision experience with a demonstration of fitting multifocal contact lenses.

As part of the educational presentations at the conference, Johnson & Johnson Vision will host sessions with themes of addressing myths and misconceptions around soft contact lenses, and maximising success for presbyopic patients.

The company will also deliver research papers covering contact lens discomfort, tear film, and presbyopia and toric, and scientific posters on, An Integrated Analysis of Six Trials Evaluating the Clinical Performance of a New Soft Contact Lens, and Comfort Advantages Demonstrated with a New Soft Contact Lens, by Dr John R. Buch, senior principal research optometrist, at Johnson & Johnson Vision.

Menicon’s health focus

Menicon will share updates on its latest developments, including an introduction to the company’s myopia management treatment plan, Menicon Bloom, delivered by head of professional services, Josie Barlow.

Read more from Barlow about Menicon’s approach to myopia management in OT’s April interview.

Henrik Bo Larsen, European professional services manager for Menicon, will discuss ways to engage new and lapsed wearers with product benefits, and the company’s Miru 1day Flat Pack contact lens.

Further talks from Menicon professionals will cover topics relating to: contact lens induced dry eye, orthokeratology lens wear in children, and myopia management.

Menicon’s stand will offer visitors healthy drinks, and reusable cups made from recycled materials, with one tree planted for each cup received.

SightGlass Vision’s DOT

SightGlass Vision will present new scientific studies with its myopia management lens at the conference, covering efficacy, quality of vision, and peripheral visual function.

SightGlass Vision’s Diffusion Optics Technology (DOT) uses thousands of micro dots to scatter light and reduce contrast on the retina.

The company, which began operating as a joint venture of CooperCompanies and EssilorLuxottica in March 2022, will share for the first time data from its study: Three-year Myopia Control Efficacy of DOT Spectacle Lenses in Young Children (Laughton D., et al.).

SightGlass Vision will also share findings exploring experiences of the lens, and reviewing long-term changes in peripheral visual acuity after three years of DOT lens wear.

The company has organised one of eight peer review track sessions at the conference: How do myopia management therapies work and does it matter?

The session is led by Professors Nicola Logan and James Wolffsohn, and the company recommends pre-booking.